EGFR and lung carcinoma: Previous studies have shown a crosstalk between the estrogen receptor and epidermal growth factor receptor (EGFR) signaling pathway, a known molecular driver of lung cancer [8] (a crosstalk that is conceptually similar to the well-documented one in the immune–angiogenic oncological pathways [9] which are targeted to improve treatment response [10]).